Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Vasopressor Exposure Levels: This is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.

Study summary

The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is:

Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.

Eligibility

Primary outcome measure(s)

• 30-Day All-Cause Mortality — From ECMO initiation through hospital discharge (assessed up to 6 months).
  The proportion of patients who die from any cause within 30 days following ECMO initiation.

Trial sites (1)

More Xiaotong Hou trials in China

Other trials for the same condition